RFCA
REGN icon

R&F Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

R&F Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1M Sell
2,594
-2
-0.1% -$741 0.26% 92
2016
Q4 		$953K Buy
+2,596
New +$987K 0.34% 75

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

R&F Capital Advisors's REGN Position: Q1 2017 in Review

R&F Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 0.08% in Q1 2017, selling an estimated $741 and leaving 2,594 shares worth $1M. The position accounts for 0.26% of the portfolio, ranked #92.

R&F Capital Advisors first reported a position in REGN in Q4 2016 and has held it in 2 quarters since. 579 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

  • R&F Capital Advisors held 2,594 shares of Regeneron Pharmaceuticals worth $1M as of Q1 2017.
  • R&F Capital Advisors sold 2 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $741.
  • Regeneron Pharmaceuticals made up 0.26% of R&F Capital Advisors's portfolio in Q1 2017, its #92 holding.
  • R&F Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 2 quarters since.
  • 579 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.